Gallbladder Cancer
FDA approves Ziihera for advanced HER2-positive biliary tract cancer
The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer.
Adjuvant durvalumab extends survival in limited-stage small cell lung cancer
Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.
New benchmark standards reveal high level of gallbladder cancer surgery complications
One-fifth of patients who underwent gallbladder cancer surgery at top-performing centers experienced related complications within 90 days, according to results of a retrospective study published in Annals of Surgical Oncology.
Zanidatamab induces response in refractory HER2-positive biliary tract cancer
CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.
Biological sex differences may explain why men face higher cancer risk than women
Men appeared to have a higher risk for cancer than women at most shared anatomic sites, according to study results published in Cancer.
FDA grants orphan drug designation to silmitasertib for biliary tract cancer
The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.